South Korea’s Celltrion to acquire Takeda portfolio

15 June 2020 - Deborah Wilkes

Premium

South Korean biopharmaceutical company Celltrion is acquiring a portfolio of prescription and OTC brands from Japan’s Takeda in a deal worth up to USD278 million.

Click tags below for more information on topics:

Takeda

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: